(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 118.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Liquidia's revenue in 2024 is $17,488,000.On average, 3 Wall Street analysts forecast LQDA's revenue for 2024 to be $3,466,106,308, with the lowest LQDA revenue forecast at $1,454,411,355, and the highest LQDA revenue forecast at $5,702,083,200. On average, 3 Wall Street analysts forecast LQDA's revenue for 2025 to be $8,943,907,569, with the lowest LQDA revenue forecast at $1,601,144,963, and the highest LQDA revenue forecast at $16,665,288,499.
In 2026, LQDA is forecast to generate $13,695,643,569 in revenue, with the lowest revenue forecast at $1,942,509,677 and the highest revenue forecast at $27,149,518,810.